The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes

The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes

Real-world use of oral and subcutaneous semaglutide in routine clinical practice in the UK: a single-centre, retrospective observational study

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial 

Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence

The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus

Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China

Defining the role of SGLT2 inhibitors in primary care: time to think differently

Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study 

Cardiorenal disease in the United States: future health care burden and potential impact of novel therapies

Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial